Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer

Zhitomirsky, B.; Assaraf, Y.G. Lysosomes as mediators of drug resistance in cancer. Drug Resist. Updat., 2016, 24, 23-33.
[http://dx.doi.org/10.1016/j.drup.2015.11.004] [PMID: 26830313]

Piao, S.; Amaravadi, R.K. Targeting the lysosome in cancer. Ann. N. Y. Acad. Sci., 2016, 1371(1), 45-54.
[http://dx.doi.org/10.1111/nyas.12953] [PMID: 26599426]

Dielschneider, R.F.; Henson, E.S.; Gibson, S.B. Lysosomes as oxidative targets for cancer therapy. Oxid. Med. Cell. Longev., 2017, 2017, 1-8.
[http://dx.doi.org/10.1155/2017/3749157] [PMID: 28757908]

Palmieri, M.; Impey, S.; Kang, H.; di Ronza, A.; Pelz, C.; Sardiello, M.; Ballabio, A. Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. Hum. Mol. Genet., 2011, 20(19), 3852-3866.
[http://dx.doi.org/10.1093/hmg/ddr306] [PMID: 21752829]

Sardiello, M.; Palmieri, M.; di Ronza, A.; Medina, D.L.; Valenza, M.; Gennarino, V.A.; Di Malta, C.; Donaudy, F.; Embrione, V.; Polishchuk, R.S.; Banfi, S.; Parenti, G.; Cattaneo, E.; Ballabio, A. A gene network regulating lysosomal biogenesis and function. Science, 2009, 325(5939), 473-477.
[http://dx.doi.org/10.1126/science.1174447] [PMID: 19556463]

Settembre, C.; Zoncu, R.; Medina, D.L.; Vetrini, F.; Erdin, S.; Erdin, S.; Huynh, T.; Ferron, M.; Karsenty, G.; Vellard, M.C.; Facchinetti, V.; Sabatini, D.M.; Ballabio, A. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J., 2012, 31(5), 1095-1108.
[http://dx.doi.org/10.1038/emboj.2012.32] [PMID: 22343943]

Saftig, P.; Klumperman, J. Lysosome biogenesis and lysosomal membrane proteins: Trafficking meets function. Nat. Rev. Mol. Cell Biol., 2009, 10(9), 623-635.
[http://dx.doi.org/10.1038/nrm2745] [PMID: 19672277]

Settembre, C.; Ballabio, A. Lysosomal adaptation: How the lysosome responds to external cues. Cold Spring Harb. Perspect. Biol., 2014, 6(6), a016907.
[http://dx.doi.org/10.1101/cshperspect.a016907] [PMID: 24799353]

Aits, S.; Jäättelä, M. Lysosomal cell death at a glance. J. Cell Sci., 2013, 126(9), 1905-1912.
[http://dx.doi.org/10.1242/jcs.091181] [PMID: 23720375]

Kroemer, G.; Jäättelä, M. Lysosomes and autophagy in cell death control. Nat. Rev. Cancer, 2005, 5(11), 886-897.
[http://dx.doi.org/10.1038/nrc1738] [PMID: 16239905]

Settembre, C.; Fraldi, A.; Medina, D.L.; Ballabio, A. Signals from the lysosome: A control centre for cellular clearance and energy metabolism. Nat. Rev. Mol. Cell Biol., 2013, 14(5), 283-296.
[http://dx.doi.org/10.1038/nrm3565] [PMID: 23609508]

Geisslinger, F.; Müller, M.; Vollmar, A.M.; Bartel, K. Targeting lysosomes in cancer as promising strategy to overcome chemoresistance - A mini review. Front. Oncol., 2020, 10, 1156.
[http://dx.doi.org/10.3389/fonc.2020.01156] [PMID: 32733810]

Chakraborty, S.; Rahman, T. The difficulties in cancer treatment. Ecancermedicalscience, 2012, 6, ed16.
[http://dx.doi.org/10.3332/ecancer.2012.ed16] [PMID: 24883085]

Zugazagoitia, J.; Guedes, C.; Ponce, S.; Ferrer, I.; Molina-Pinelo, S.; Paz-Ares, L. Current challenges in cancer treatment. Clin. Ther., 2016, 38(7), 1551-1566.
[http://dx.doi.org/10.1016/j.clinthera.2016.03.026] [PMID: 27158009]

Vasan, N.; Baselga, J.; Hyman, D.M. A view on drug resistance in cancer. Nature, 2019, 575(7782), 299-309.
[http://dx.doi.org/10.1038/s41586-019-1730-1] [PMID: 31723286]

Halaby, R. Influence of lysosomal sequestration on multidrug resistance in cancer cells. Cancer Drug Resist., 2019, 2(1), 31-42.
[http://dx.doi.org/10.20517/cdr.2018.23] [PMID: 35582144]

Goldman, S.D.B.; Funk, R.S.; Rajewski, R.A.; Krise, J.P. Mechanisms of amine accumulation in, and egress from, lysosomes. Bioanalysis, 2009, 1(8), 1445-1459.
[http://dx.doi.org/10.4155/bio.09.128] [PMID: 21083094]

Kazmi, F.; Hensley, T.; Pope, C.; Funk, R.S.; Loewen, G.J.; Buckley, D.B.; Parkinson, A. Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells). Drug Metab. Dispos., 2013, 41(4), 897-905.
[http://dx.doi.org/10.1124/dmd.112.050054] [PMID: 23378628]

Gotink, K.J.; Broxterman, H.J.; Labots, M.; de Haas, R.R.; Dekker, H.; Honeywell, R.J.; Rudek, M.A.; Beerepoot, L.V.; Musters, R.J.; Jansen, G.; Griffioen, A.W.; Assaraf, Y.G.; Pili, R.; Peters, G.J.; Verheul, H.M.W. Lysosomal sequestration of sunitinib: A novel mechanism of drug resistance. Clin. Cancer Res., 2011, 17(23), 7337-7346.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-1667] [PMID: 21980135]

Hraběta, J.; Belhajová, M.; Šubrtová, H.; Merlos Rodrigo, M.A.; Heger, Z.; Eckschlager, T. Drug sequestration in lysosomes as one of the mechanisms of chemoresistance of cancer Cells and the possibilities of its inhibition. Int. J. Mol. Sci., 2020, 21(12), 4392.
[http://dx.doi.org/10.3390/ijms21124392] [PMID: 32575682]

Adar, Y.; Stark, M.; Bram, E.E.; Nowak-Sliwinska, P.; van den Bergh, H.; Szewczyk, G.; Sarna, T.; Skladanowski, A.; Griffioen, A.W.; Assaraf, Y.G. Imidazoacridinone-dependent lysosomal photodestruction: A pharmacological Trojan horse approach to eradicate multidrug-resistant cancers. Cell Death Dis., 2012, 3(4), e293.
[http://dx.doi.org/10.1038/cddis.2012.30] [PMID: 22476101]

Herlevsen, M.; Oxford, G.; Owens, C.R.; Conaway, M.; Theodorescu, D. Depletion of major vault protein increases doxorubicin sensitivity and nuclear accumulation and disrupts its sequestration in lysosomes. Mol. Cancer Ther., 2007, 6(6), 1804-1813.
[http://dx.doi.org/10.1158/1535-7163.MCT-06-0372] [PMID: 17575109]

Ndolo, R.A.; Luan, Y.; Duan, S.; Forrest, M.L.; Krise, J.P. Lysosomotropic properties of weakly basic anticancer agents promote cancer cell selectivity in vitro. PLoS One, 2012, 7(11), e49366.
[http://dx.doi.org/10.1371/journal.pone.0049366] [PMID: 23145164]

Marshall, L.A.; Rhee, M.S.; Hofmann, L.; Khodjakov, A.; Schneider, E. Increased lysosomal uptake of methotrexate-polyglutamates in two methotrexate-resistant cell lines with distinct mechanisms of resistance. Biochem. Pharmacol., 2005, 71(1-2), 203-213.
[http://dx.doi.org/10.1016/j.bcp.2005.10.008] [PMID: 16263093]

Zhitomirsky, B.; Assaraf, Y.G. Correction: Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance. Oncotarget, 2022, 13(1), 585-586.
[http://dx.doi.org/10.18632/oncotarget.28110] [PMID: 35391719]

Mohammadabadi, M.R.; Mozafari, M.R. Enhanced efficacy and bioavailability of thymoquinone using nanoliposomal dosage form. J. Drug Deliv. Sci. Technol., 2018, 47, 445-453.
[http://dx.doi.org/10.1016/j.jddst.2018.08.019]

Barazandeh, H.; Kissane, D.W.; Saeedi, N.; Gordon, M. A systematic review of the relationship between early maladaptive schemas and borderline personality disorder/traits. Pers. Individ. Dif., 2016, 94, 130-139.
[http://dx.doi.org/10.1016/j.paid.2016.01.021]

Barazandeh, A.; Mohammadabadi, M.R.; Ghaderi-Zefrehei, M.; Nezamabadi-pour, H. Genome-wide analysis of CpG islands in some livestock genomes and their relationship with genomic features. Czech J. Anim. Sci., 2016, 61(11), 487-495.
[http://dx.doi.org/10.17221/78/2015-CJAS]

Zarrabi, A.J.; Welsh, J.W.; Sniecinski, R.; Curseen, K.; Gillespie, T.; Baer, W.; McKenzie-Brown, A.M.; Singh, V. Perception of benefits and harms of medical cannabis among seriously Ill patients in an outpatient palliative care practice. J. Palliat. Med., 2020, 23(4), 558-562.
[http://dx.doi.org/10.1089/jpm.2019.0211] [PMID: 31539298]

Allemailem, K.S.; Almatroudi, A.; Alrumaihi, F.; Almatroodi, S.A.; Alkurbi, M.O.; Basfar, G.T.; Rahmani, A.H.; Khan, A.A. Novel approaches of dysregulating lysosome functions in cancer cells by specific drugs and its nanoformulations: A smart approach of modern therapeutics. Int. J. Nanomedicine, 2021, 16, 5065-5098.
[http://dx.doi.org/10.2147/IJN.S321343] [PMID: 34345172]

Li, F.; Wang, W.; Lai, G.; Lan, S.; Lv, L.; Wang, S.; Liu, X.; Zheng, J. Development and validation of a novel lysosome-related LncRNA signature for predicting prognosis and the immune landscape features in colon cancer. Sci. Rep., 2024, 14(1), 622.
[http://dx.doi.org/10.1038/s41598-023-51126-9] [PMID: 38182713]

Tang, T.; Yang, Z.; Wang, D.; Yang, X.; Wang, J.; Li, L.; Wen, Q.; Gao, L.; Bian, X.; Yu, S. The role of lysosomes in cancer development and progression. Cell Biosci., 2020, 10(1), 131.
[http://dx.doi.org/10.1186/s13578-020-00489-x] [PMID: 33292489]

Pal, S.; Sharma, A.; Mathew, S.P.; Jaganathan, B.G. Targeting cancer-specific metabolic pathways for developing novel cancer therapeutics. Front. Immunol., 2022, 13, 955476.
[http://dx.doi.org/10.3389/fimmu.2022.955476] [PMID: 36618350]

Commisso, C.; Davidson, S.M.; Soydaner-Azeloglu, R.G.; Parker, S.J.; Kamphorst, J.J.; Hackett, S.; Grabocka, E.; Nofal, M.; Drebin, J.A.; Thompson, C.B.; Rabinowitz, J.D.; Metallo, C.M.; Vander Heiden, M.G.; Bar-Sagi, D. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature, 2013, 497(7451), 633-637.
[http://dx.doi.org/10.1038/nature12138] [PMID: 23665962]

Mosesson, Y.; Mills, G.B.; Yarden, Y. Derailed endocytosis: An emerging feature of cancer. Nat. Rev. Cancer, 2008, 8(11), 835-850.
[http://dx.doi.org/10.1038/nrc2521] [PMID: 18948996]

Perera, R.M.; Bardeesy, N. Pancreatic cancer metabolism: Breaking it down to build it back up. Cancer Discov., 2015, 5(12), 1247-1261.
[http://dx.doi.org/10.1158/2159-8290.CD-15-0671] [PMID: 26534901]

MDuff F.K.E.; Turner, S.D.; Jailbreak, D. Jailbreak: Oncogene-induced senescence and its evasion. Cell. Signal., 2011, 23(1), 6-13.
[http://dx.doi.org/10.1016/j.cellsig.2010.07.004] [PMID: 20633638]

Collado, M.; Gil, J.; Efeyan, A.; Guerra, C.; Schuhmacher, A.J.; Barradas, M.; Benguría, A.; Zaballos, A.; Flores, J.M.; Barbacid, M.; Beach, D.; Serrano, M. Senescence in premalignant tumours. Nature, 2005, 436(7051), 642.
[http://dx.doi.org/10.1038/436642a] [PMID: 16079833]

Braig, M.; Lee, S.; Loddenkemper, C.; Rudolph, C.; Peters, A.H.F.M.; Schlegelberger, B.; Stein, H.; Dörken, B.; Jenuwein, T.; Schmitt, C.A. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature, 2005, 436(7051), 660-665.
[http://dx.doi.org/10.1038/nature03841] [PMID: 16079837]

Chen, Z.; Trotman, L.C.; Shaffer, D.; Lin, H.K.; Dotan, Z.A.; Niki, M.; Koutcher, J.A.; Scher, H.I.; Ludwig, T.; Gerald, W.; Cordon-Cardo, C.; Paolo Pandolfi, P. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature, 2005, 436(7051), 725-730.
[http://dx.doi.org/10.1038/nature03918] [PMID: 16079851]

Dankort, D.; Filenova, E.; Collado, M.; Serrano, M.; Jones, K.; McMahon, M. A new mouse model to explore the initiation, progression, and therapy of BRAF V600E -induced lung tumors. Genes Dev., 2007, 21(4), 379-384.
[http://dx.doi.org/10.1101/gad.1516407] [PMID: 17299132]

Ivanov, A.; Pawlikowski, J.; Manoharan, I.; van Tuyn, J.; Nelson, D.M.; Rai, T.S.; Shah, P.P.; Hewitt, G.; Korolchuk, V.I.; Passos, J.F.; Wu, H.; Berger, S.L.; Adams, P.D. Lysosome-mediated processing of chromatin in senescence. J. Cell Biol., 2013, 202(1), 129-143.
[http://dx.doi.org/10.1083/jcb.201212110] [PMID: 23816621]

Halaby, R. Role of lysosomes in cancer therapy. Res. Rep. Biol., 2015, 6, 147-155.
[http://dx.doi.org/10.2147/RRB.S83999]

Guo, J.Y.; Karsli-Uzunbas, G.; Mathew, R.; Aisner, S.C.; Kamphorst, J.J.; Strohecker, A.M.; Chen, G.; Price, S.; Lu, W.; Teng, X.; Snyder, E.; Santanam, U.; DiPaola, R.S.; Jacks, T.; Rabinowitz, J.D.; White, E. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev., 2013, 27(13), 1447-1461.
[http://dx.doi.org/10.1101/gad.219642.113] [PMID: 23824538]

Rao, S.; Tortola, L.; Perlot, T.; Wirnsberger, G.; Novatchkova, M.; Nitsch, R.; Sykacek, P.; Frank, L.; Schramek, D.; Komnenovic, V.; Sigl, V.; Aumayr, K.; Schmauss, G.; Fellner, N.; Handschuh, S.; Glösmann, M.; Pasierbek, P.; Schlederer, M.; Resch, G.P.; Ma, Y.; Yang, H.; Popper, H.; Kenner, L.; Kroemer, G.; Penninger, J.M. A dual role for autophagy in a murine model of lung cancer. Nat. Commun., 2014, 5(1), 3056.
[http://dx.doi.org/10.1038/ncomms4056] [PMID: 24445999]

Xie, X.; Koh, J.Y.; Price, S.; White, E.; Mehnert, J.M. Atg7 Overcomes senescence and promotes growth of BrafV600E-driven melanoma. Cancer Discov., 2015, 5(4), 410-423.
[http://dx.doi.org/10.1158/2159-8290.CD-14-1473] [PMID: 25673642]

Lévy, J.; Cacheux, W.; Bara, M.A.; L’Hermitte, A.; Lepage, P.; Fraudeau, M.; Trentesaux, C.; Lemarchand, J.; Durand, A.; Crain, A.M.; Marchiol, C.; Renault, G.; Dumont, F.; Letourneur, F.; Delacre, M.; Schmitt, A.; Terris, B.; Perret, C.; Chamaillard, M.; Couty, J.P.; Romagnolo, B. Intestinal inhibition of Atg7 prevents tumour initiation through a microbiome-influenced immune response and suppresses tumour growth. Nat. Cell Biol., 2015, 17(8), 1062-1073.
[http://dx.doi.org/10.1038/ncb3206] [PMID: 26214133]

Santanam, U.; Banach-Petrosky, W.; Abate-Shen, C.; Shen, M.M.; White, E.; DiPaola, R.S. Atg7 cooperates with Pten loss to drive prostate cancer tumor growth. Genes Dev., 2016, 30(4), 399-407.
[http://dx.doi.org/10.1101/gad.274134.115] [PMID: 26883359]

Yeo, S.K.; Wen, J.; Chen, S.; Guan, J.L. Autophagy differentially regulates distinct breast cancer stem-like cells in murine models via EGFR/Stat3 and Tgfβ/Smad signaling. Cancer Res., 2016, 76(11), 3397-3410.
[http://dx.doi.org/10.1158/0008-5472.CAN-15-2946] [PMID: 27197172]

Morelli, M.B.; Nabissi, M.; Amantini, C.; Tomassoni, D.; Rossi, F.; Cardinali, C.; Santoni, M.; Arcella, A.; Oliva, M.A.; Santoni, A.; Polidori, C.; Mariani, M.P.; Santoni, G. Overexpression of transient receptor potential mucolipin-2 ion channels in gliomas: Role in tumor growth and progression. Oncotarget, 2016, 7(28), 43654-43668.
[http://dx.doi.org/10.18632/oncotarget.9661] [PMID: 27248469]

Liu, H.; Ma, Y.; He, H.W.; Zhao, W.L.; Shao, R.G. SPHK1 (sphingosine kinase 1) induces epithelial-mesenchymal transition by promoting the autophagy-linked lysosomal degradation of CDH1/E-cadherin in hepatoma cells. Autophagy, 2017, 13(5), 900-913.
[http://dx.doi.org/10.1080/15548627.2017.1291479] [PMID: 28521610]

Zhang, W.; Yuan, W.; Song, J.; Wang, S.; Gu, X. LncRNA CPS1-IT1 suppresses EMT and metastasis of colorectal cancer by inhibiting hypoxia-induced autophagy through inactivation of HIF-1α. Biochimie, 2018, 144, 21-27.
[http://dx.doi.org/10.1016/j.biochi.2017.10.002] [PMID: 29017924]

Wu, W.J.; Hirsch, D.S. Mechanism of E-cadherin lysosomal degradation. Nat. Rev. Cancer, 2009, 9(2), 143.
[http://dx.doi.org/10.1038/nrc2521-c1] [PMID: 19148182]

Fiore, L.S.; Ganguly, S.S.; Sledziona, J.; Cibull, M.L.; Wang, C.; Richards, D.L.; Neltner, J.M.; Beach, C.; McCorkle, J.R.; Kaetzel, D.M.; Plattner, R. c-Abl and Arg induce cathepsin-mediated lysosomal degradation of the NM23-H1 metastasis suppressor in invasive cancer. Oncogene, 2014, 33(36), 4508-4520.
[http://dx.doi.org/10.1038/onc.2013.399] [PMID: 24096484]

Sharifi, M.N.; Mowers, E.E.; Drake, L.E.; Collier, C.; Chen, H.; Zamora, M.; Mui, S.; Macleod, K.F. Autophagy promotes focal adhesion disassembly and cell motility of metastatic tumor cells through the direct interaction of paxillin with LC. Cell Rep., 2016, 15(8), 1660-1672.
[http://dx.doi.org/10.1016/j.celrep.2016.04.065] [PMID: 27184837]

Lock, R.; Kenific, C.M.; Leidal, A.M.; Salas, E.; Debnath, J. Autophagy-dependent production of secreted factors facilitates oncogenic RAS-driven invasion. Cancer Discov., 2014, 4(4), 466-479.
[http://dx.doi.org/10.1158/2159-8290.CD-13-0841] [PMID: 24513958]

Endres, M.; Kneitz, S.; Orth, M.F.; Perera, R.K.; Zernecke, A.; Butt, E. Regulation of matrix metalloproteinases (MMPs) expression and secretion in MDA-MB-231 breast cancer cells by LIM and SH3 protein 1 (LASP1). Oncotarget, 2016, 7(39), 64244-64259.
[http://dx.doi.org/10.18632/oncotarget.11720] [PMID: 27588391]

Mohsen, A.; Collery, P.; Garnotel, R.; Brassart, B.; Etique, N.; Mohamed Sabry, G.; Elsherif Hassan, R.; Jeannesson, P.; Desmaële, D.; Morjani, H. A new gallium complex inhibits tumor cell invasion and matrix metalloproteinase MMP-14 expression and activity. Metallomics, 2017, 9(8), 1176-1184.
[http://dx.doi.org/10.1039/C7MT00049A] [PMID: 28765844]

Grimm, C.; Bartel, K.; Vollmar, A.; Biel, M. Endolysosomal cation channels and cancer-A link with great potential. Pharmaceuticals, 2018, 11(1), 4.
[http://dx.doi.org/10.3390/ph11010004] [PMID: 29303993]

Lyu, L.; Jin, X.; Li, Z.; Liu, S.; Li, Y.; Su, R.; Su, H. TBBPA regulates calcium-mediated lysosomal exocytosis and thereby promotes invasion and migration in hepatocellular carcinoma. Ecotoxicol. Environ. Saf., 2020, 192, 110255.
[http://dx.doi.org/10.1016/j.ecoenv.2020.110255] [PMID: 32018154]

Withana, N.P.; Blum, G.; Sameni, M.; Slaney, C.; Anbalagan, A.; Olive, M.B.; Bidwell, B.N.; Edgington, L.; Wang, L.; Moin, K.; Sloane, B.F.; Anderson, R.L.; Bogyo, M.S.; Parker, B.S. Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res., 2012, 72(5), 1199-1209.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-2759] [PMID: 22266111]

Keliher, E.J.; Reiner, T.; Earley, S.; Klubnick, J.; Tassa, C.; Lee, A.J.; Ramaswamy, S.; Bardeesy, N.; Hanahan, D.; DePinho, R.A.; Castro, C.M.; Weissleder, R. Targeting cathepsin E in pancreatic cancer by a small molecule allows in vivo detection. Neoplasia, 2013, 15(7), 684-IN3.
[http://dx.doi.org/10.1593/neo.13276] [PMID: 23814481]

Small, D.M.; Burden, R.E.; Jaworski, J.; Hegarty, S.M.; Spence, S.; Burrows, J.F.; McFarlane, C.; Kissenpfennig, A.; McCarthy, H.O.; Johnston, J.A.; Walker, B.; Scott, C.J. Cathepsin S from both tumor and tumor-associated cells promote cancer growth and neovascularization. Int. J. Cancer, 2013, 133(9), 2102-2112.
[http://dx.doi.org/10.1002/ijc.28238] [PMID: 23629809]

Morgan, M.J.; Fitzwalter, B.E.; Owens, C.R.; Powers, R.K.; Sottnik, J.L.; Gamez, G.; Costello, J.C.; Theodorescu, D.; Thorburn, A. Metastatic cells are preferentially vulnerable to lysosomal inhibition. Proc. Natl. Acad. Sci., 2018, 115(36), E8479-E8488.
[http://dx.doi.org/10.1073/pnas.1706526115] [PMID: 30127018]

Bluff, J.E.; Menakuru, S.R.; Cross, S.S.; Higham, S.E.; Balasubramanian, S.P.; Brown, N.J.; Reed, M.W.; Staton, C.A. Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease. Br. J. Cancer, 2009, 101(4), 666-672.
[http://dx.doi.org/10.1038/sj.bjc.6605196] [PMID: 19623180]

Carmeliet, P. Angiogenesis in health and disease. Nat. Med., 2003, 9(6), 653-660.
[http://dx.doi.org/10.1038/nm0603-653] [PMID: 12778163]

Joyce, J.A.; Baruch, A.; Chehade, K.; Meyer-Morse, N.; Giraudo, E.; Tsai, F.Y.; Greenbaum, D.C.; Hager, J.H.; Bogyo, M.; Hanahan, D. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell, 2004, 5(5), 443-453.
[http://dx.doi.org/10.1016/S1535-6108(04)00111-4] [PMID: 15144952]

Kallunki, T.; Olsen, O.D.; Jäättelä, M. Cancer-associated lysosomal changes: Friends or foes? Oncogene, 2013, 32(16), 1995-2004.
[http://dx.doi.org/10.1038/onc.2012.292] [PMID: 22777359]

Jiang, H.; Wu, Cheng X.; Shi, G.P.; Hu, L.; Inoue, A.; Yamamura, Y.; Wu, H.; Takeshita, K.; Li, X.; Huang, Z.; Song, H.; Asai, M.; Hao, C.N.; Unno, K.; Koike, T.; Oshida, Y.; Okumura, K.; Murohara, T.; Kuzuya, M. Cathepsin K-mediated notch1 activation contributes to neovascularization in response to hypoxia. Nat. Commun., 2014, 5(1), 3838.
[http://dx.doi.org/10.1038/ncomms4838] [PMID: 24894568]

Jopling, H.; Odell, A.; Pellet-Many, C.; Latham, A.; Frankel, P.; Sivaprasadarao, A.; Walker, J.; Zachary, I.; Ponnambalam, S. Endosome-to-plasma membrane recycling of VEGFR2 receptor tyrosine kinase regulates endothelial function and blood vessel formation. Cells, 2014, 3(2), 363-385.
[http://dx.doi.org/10.3390/cells3020363] [PMID: 24785348]

Favia, A.; Desideri, M.; Gambara, G.; D’Alessio, A.; Ruas, M.; Esposito, B.; Del Bufalo, D.; Parrington, J.; Ziparo, E.; Palombi, F.; Galione, A.; Filippini, A. VEGF-induced neoangiogenesis is mediated by NAADP and two-pore channel-2–dependent Ca 2+ signaling. Proc. Natl. Acad. Sci., 2014, 111(44), E4706-E4715.
[http://dx.doi.org/10.1073/pnas.1406029111] [PMID: 25331892]

Intlekofer, A.M.; Thompson, C.B. At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J. Leukoc. Biol., 2013, 94(1), 25-39.
[http://dx.doi.org/10.1189/jlb.1212621] [PMID: 23625198]

Wang, H.; Han, X.; Xu, J. Lysosome as the black hole for checkpoint molecules. Adv. Exp. Med. Biol., 2020, 1248, 325-346.
[http://dx.doi.org/10.1007/978-981-15-3266-5_14] [PMID: 32185717]

Casey, T.M.; Meade, J.L.; Hewitt, E.W. Organelle proteomics. Mol. Cell. Proteomics, 2007, 6(5), 767-780.
[http://dx.doi.org/10.1074/mcp.M600365-MCP200] [PMID: 17272266]

Tofilon, P.J.; Fike, J.R. The radioresponse of the central nervous system: A dynamic process. Radiat. Res., 2000, 153(4), 357-370.
[http://dx.doi.org/10.1667/0033-7587(2000)153[0357:TROTCN]2.0.CO;2] [PMID: 10798963]

Samie, M.; Wang, X.; Zhang, X.; Goschka, A.; Li, X.; Cheng, X.; Gregg, E.; Azar, M.; Zhuo, Y.; Garrity, A.G.; Gao, Q.; Slaugenhaupt, S.; Pickel, J.; Zolov, S.N.; Weisman, L.S.; Lenk, G.M.; Titus, S.; Bryant-Genevier, M.; Southall, N.; Juan, M.; Ferrer, M.; Xu, H. A TRP channel in the lysosome regulates large particle phagocytosis via focal exocytosis. Dev. Cell, 2013, 26(5), 511-524.
[http://dx.doi.org/10.1016/j.devcel.2013.08.003] [PMID: 23993788]

Aras, S.; Zaidi, M.R. TAMeless traitors: Macrophages in cancer progression and metastasis. Br. J. Cancer, 2017, 117(11), 1583-1591.
[http://dx.doi.org/10.1038/bjc.2017.356] [PMID: 29065107]

Sun, L.; Hua, Y.; Vergarajauregui, S.; Diab, H.I.; Puertollano, R. Novel role of TRPML2 in the regulation of the innate immune response. J. Immunol., 2015, 195(10), 4922-4932.
[http://dx.doi.org/10.4049/jimmunol.1500163] [PMID: 26432893]

Plesch, E.; Chen, C.C.; Butz, E.; Scotto Rosato, A.; Krogsaeter, E.K.; Yinan, H.; Bartel, K.; Keller, M.; Robaa, D.; Teupser, D.; Holdt, L.M.; Vollmar, A.M.; Sippl, W.; Puertollano, R.; Medina, D.; Biel, M.; Wahl-Schott, C.; Bracher, F.; Grimm, C. Selective agonist of TRPML2 reveals direct role in chemokine release from innate immune cells. eLife, 2018, 7, e39720.
[http://dx.doi.org/10.7554/eLife.39720] [PMID: 30479274]

Mirzaei, S.; Gholami, M.H.; Hashemi, F.; Zabolian, A.; Farahani, M.V.; Hushmandi, K.; Zarrabi, A.; Goldman, A.; Ashrafizadeh, M.; Orive, G. Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects. Drug Discov. Today, 2022, 27(2), 436-455.
[http://dx.doi.org/10.1016/j.drudis.2021.09.020] [PMID: 34624510]

Machado, E.R.; Annunziata, I.; van de Vlekkert, D.; Grosveld, G.C.; d’Azzo, A. Lysosomes and cancer progression: A malignant liaison. Front. Cell Dev. Biol., 2021, 9, 642494.
[http://dx.doi.org/10.3389/fcell.2021.642494] [PMID: 33718382]

Yamagishi, T.; Sahni, S.; Sharp, D.M.; Arvind, A.; Jansson, P.J.; Richardson, D.R. P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J. Biol. Chem., 2013, 288(44), 31761-31771.
[http://dx.doi.org/10.1074/jbc.M113.514091] [PMID: 24062304]

Al-Akra, L.; Bae, D.H.; Sahni, S.; Huang, M.L.H.; Park, K.C.; Lane, D.J.R.; Jansson, P.J.; Richardson, D.R. Tumor stressors induce two mechanisms of intracellular P-glycoprotein–mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones. J. Biol. Chem., 2018, 293(10), 3562-3587.
[http://dx.doi.org/10.1074/jbc.M116.772699] [PMID: 29305422]

Noack, A.; Gericke, B.; von Köckritz-Blickwede, M.; Menze, A.; Noack, S.; Gerhauser, I.; Osten, F.; Naim, H.Y.; Löscher, W. Mechanism of drug extrusion by brain endothelial cells via lysosomal drug trapping and disposal by neutrophils. Proc. Natl. Acad. Sci., 2018, 115(41), E9590-E9599.
[http://dx.doi.org/10.1073/pnas.1719642115] [PMID: 30254169]

Grimm, C.; Holdt, L.M.; Chen, C.C.; Hassan, S.; Müller, C.; Jörs, S.; Cuny, H.; Kissing, S.; Schröder, B.; Butz, E.; Northoff, B.; Castonguay, J.; Luber, C.A.; Moser, M.; Spahn, S.; Lüllmann-Rauch, R.; Fendel, C.; Klugbauer, N.; Griesbeck, O.; Haas, A.; Mann, M.; Bracher, F.; Teupser, D.; Saftig, P.; Biel, M.; Wahl-Schott, C. High susceptibility to fatty liver disease in two-pore channel 2-deficient mice. Nat. Commun., 2014, 5(1), 4699.
[http://dx.doi.org/10.1038/ncomms5699] [PMID: 25144390]

Schneider, L.S.; von Schwarzenberg, K.; Lehr, T.; Ulrich, M.; Kubisch-Dohmen, R.; Liebl, J.; Trauner, D.; Menche, D.; Vollmar, A.M. Vacuolar-ATPase inhibition blocks iron metabolism to mediate therapeutic effects in breast cancer. Cancer Res., 2015, 75(14), 2863-2874.
[http://dx.doi.org/10.1158/0008-5472.CAN-14-2097] [PMID: 26018087]

Whitton, B.; Okamoto, H.; Packham, G.; Crabb, S.J. Vacuolar ATPase as a potential therapeutic target and mediator of treatment resistance in cancer. Cancer Med., 2018, 7(8), 3800-3811.
[http://dx.doi.org/10.1002/cam4.1594] [PMID: 29926527]

von Schwarzenberg, K. Lajtos, T.; Simon, L.; Müller, R.; Vereb, G.; Vollmar, A.M. V-ATPase inhibition overcomes trastuzumab resistance in breast cancer. Mol. Oncol., 2014, 8(1), 9-19.
[http://dx.doi.org/10.1016/j.molonc.2013.08.011] [PMID: 24055142]

Bartel, K.; Winzi, M.; Ulrich, M.; Koeberle, A.; Menche, D.; Werz, O.; Müller, R.; Guck, J.; Vollmar, A.M.; von Schwarzenberg, K. V-ATPase inhibition increases cancer cell stiffness and blocks membrane related Ras signaling - a new option for HCC therapy. Oncotarget, 2017, 8(6), 9476-9487.
[http://dx.doi.org/10.18632/oncotarget.14339] [PMID: 28036299]

Stenmark, H. Rab GTPases as coordinators of vesicle traffic. Nat. Rev. Mol. Cell Biol., 2009, 10(8), 513-525.
[http://dx.doi.org/10.1038/nrm2728] [PMID: 19603039]

Fu, D.; Arias, I.M. Intracellular trafficking of P-glycoprotein. Int. J. Biochem. Cell Biol., 2012, 44(3), 461-464.
[http://dx.doi.org/10.1016/j.biocel.2011.12.009] [PMID: 22212176]

Stark, M.; Silva, T.F.D.; Levin, G.; Machuqueiro, M.; Assaraf, Y.G. The lysosomotropic activity of hydrophobic weak base drugs is mediated via their intercalation into the lysosomal membrane. Cells, 2020, 9(5), 1082.
[http://dx.doi.org/10.3390/cells9051082] [PMID: 32349204]

Seebacher, N.; Lane, D.J.R.; Richardson, D.R.; Jansson, P.J. Turning the gun on cancer: Utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistance. Free Radic. Biol. Med., 2016, 96, 432-445.
[http://dx.doi.org/10.1016/j.freeradbiomed.2016.04.201] [PMID: 27154979]

Gericke, B.; Wienböker, I.; Brandes, G.; Löscher, W. Is P-Glycoprotein functionally expressed in the limiting membrane of endolysosomes? A biochemical and ultrastructural study in the rat liver. Cells, 2022, 11(9), 1556.
[http://dx.doi.org/10.3390/cells11091556] [PMID: 35563868]

Saha, J.; Kim, J.H.; Amaya, C.N.; Witcher, C.; Khammanivong, A.; Korpela, D.M.; Brown, D.R.; Taylor, J.; Bryan, B.A.; Dickerson, E.B. Propranolol sensitizes vascular sarcoma cells to doxorubicin by altering lysosomal drug sequestration and drug efflux. Front. Oncol., 2021, 10, 614288.
[http://dx.doi.org/10.3389/fonc.2020.614288] [PMID: 33598432]

Kokkonen, N.; Rivinoja, A.; Kauppila, A.; Suokas, M.; Kellokumpu, I.; Kellokumpu, S. Defective acidification of intracellular organelles results in aberrant secretion of cathepsin D in cancer cells. J. Biol. Chem., 2004, 279(38), 39982-39988.
[http://dx.doi.org/10.1074/jbc.M406698200] [PMID: 15258139]

Vega-Rubin-de-Celis, S.; Peña-Llopis, S.; Konda, M.; Brugarolas, J. Multistep regulation of TFEB by MTORC1. Autophagy, 2017, 13(3), 464-472.
[http://dx.doi.org/10.1080/15548627.2016.1271514] [PMID: 28055300]

Medina, D.L.; Di Paola, S.; Peluso, I.; Armani, A.; De Stefani, D.; Venditti, R.; Montefusco, S.; Scotto-Rosato, A.; Prezioso, C.; Forrester, A.; Settembre, C.; Wang, W.; Gao, Q.; Xu, H.; Sandri, M.; Rizzuto, R.; De Matteis, M.A.; Ballabio, A. Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. Nat. Cell Biol., 2015, 17(3), 288-299.
[http://dx.doi.org/10.1038/ncb3114] [PMID: 25720963]

Repnik, U.; Stoka, V.; Turk, V.; Turk, B. Lysosomes and lysosomal cathepsins in cell death. Biochim. Biophys. Acta. Proteins Proteomics, 2012, 1824(1), 22-33.
[http://dx.doi.org/10.1016/j.bbapap.2011.08.016] [PMID: 21914490]

Li, D.L.; Wang, Z.V.; Ding, G.; Tan, W.; Luo, X.; Criollo, A.; Xie, M.; Jiang, N.; May, H.; Kyrychenko, V.; Schneider, J.W.; Gillette, T.G.; Hill, J.A. Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification. Circulation, 2016, 133(17), 1668-1687.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.115.017443] [PMID: 26984939]

Zhang, Z.; Yue, P.; Lu, T.; Wang, Y.; Wei, Y.; Wei, X. Role of lysosomes in physiological activities, diseases, and therapy. J. Hematol. Oncol., 2021, 14(1), 79.
[http://dx.doi.org/10.1186/s13045-021-01087-1] [PMID: 33990205]

Xiao, H.; Zheng, Y.; Ma, L.; Tian, L.; Sun, Q. Clinically-relevant abc transporter for anti-cancer drug resistance. Front. Pharmacol., 2021, 12, 648407.
[http://dx.doi.org/10.3389/fphar.2021.648407] [PMID: 33953682]

Assaraf, Y.G. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist. Updat., 2006, 9(4-5), 227-246.
[http://dx.doi.org/10.1016/j.drup.2006.09.001] [PMID: 17092765]

Gillet, J.P.; Gottesman, M.M. Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. Curr. Pharm. Biotechnol., 2011, 12(4), 686-692.
[http://dx.doi.org/10.2174/138920111795163931] [PMID: 21118086]

Holohan, C.; Van Schaeybroeck, S.; Longley, D.B.; Johnston, P.G. Cancer drug resistance: An evolving paradigm. Nat. Rev. Cancer, 2013, 13(10), 714-726.
[http://dx.doi.org/10.1038/nrc3599] [PMID: 24060863]

Ferrao, P.; Sincock, P.; Cole, S.; Ashman, L. Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia. Leuk. Res., 2001, 25(5), 395-405.
[http://dx.doi.org/10.1016/S0145-2126(00)00156-9] [PMID: 11301107]

Stefan, S.M.; Jansson, P.J.; Kalinowski, D.S.; Anjum, R.; Dharmasivam, M.; Richardson, D.R. The growing evidence for targeting P-glycoprotein in lysosomes to overcome resistance. Future Med. Chem., 2020, 12(6), 473-477.
[http://dx.doi.org/10.4155/fmc-2019-0350] [PMID: 32098489]

Chapuy, B.; Koch, R.; Radunski, U.; Corsham, S.; Cheong, N.; Inagaki, N.; Ban, N.; Wenzel, D.; Reinhardt, D.; Zapf, A.; Schweyer, S.; Kosari, F.; Klapper, W.; Truemper, L.; Wulf, G.G. Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. Leukemia, 2008, 22(8), 1576-1586.
[http://dx.doi.org/10.1038/leu.2008.103] [PMID: 18463677]

Chapuy, B.; Panse, M.; Radunski, U.; Koch, R.; Wenzel, D.; Inagaki, N.; Haase, D.; Truemper, L.; Wulf, G.G. ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug. Haematologica, 2009, 94(11), 1528-1536.
[http://dx.doi.org/10.3324/haematol.2009.008631] [PMID: 19880777]

Song, I.S.; Savaraj, N.; Siddik, Z.H.; Liu, P.; Wei, Y.; Wu, C.J.; Kuo, M.T. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol. Cancer Ther., 2004, 3(12), 1543-1549.
[http://dx.doi.org/10.1158/1535-7163.1543.3.12] [PMID: 15634647]

Ishida, S.; Lee, J.; Thiele, D.J.; Herskowitz, I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl. Acad. Sci., 2002, 99(22), 14298-14302.
[http://dx.doi.org/10.1073/pnas.162491399] [PMID: 12370430]

Lin, X.; Okuda, T.; Holzer, A.; Howell, S.B. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol. Pharmacol., 2002, 62(5), 1154-1159.
[http://dx.doi.org/10.1124/mol.62.5.1154] [PMID: 12391279]

Holzer, A.K.; Samimi, G.; Katano, K.; Naerdemann, W.; Lin, X.; Safaei, R.; Howell, S.B. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol. Pharmacol., 2004, 66(4), 817-823.
[http://dx.doi.org/10.1124/mol.104.001198] [PMID: 15229296]

Lee, Y.Y.; Choi, C.H.; Do, I.G.; Song, S.Y.; Lee, W.; Park, H.S.; Song, T.J.; Kim, M.K.; Kim, T.J.; Lee, J.W.; Bae, D.S.; Kim, B.G. Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy. Gynecol. Oncol., 2011, 122(2), 361-365.
[http://dx.doi.org/10.1016/j.ygyno.2011.04.025] [PMID: 21570711]

Chen, H.H.W.; Yan, J.J.; Chen, W.C.; Kuo, M.T.; Lai, Y.H.; Lai, W.W.; Liu, H.S.; Su, W.C. Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. Lung Cancer, 2012, 75(2), 228-234.
[http://dx.doi.org/10.1016/j.lungcan.2011.06.011] [PMID: 21788094]

Kim, E.S.; Tang, X.; Peterson, D.R.; Kilari, D.; Chow, C.W.; Fujimoto, J.; Kalhor, N.; Swisher, S.G.; Stewart, D.J.; Wistuba, I.I.; Siddik, Z.H. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer, 2014, 85(1), 88-93.
[http://dx.doi.org/10.1016/j.lungcan.2014.04.005] [PMID: 24792335]

Xu, X.; Duan, L.; Zhou, B.; Ma, R.; Zhou, H.; Liu, Z. Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients. Clin. Exp. Pharmacol. Physiol., 2012, 39(9), 786-792.
[http://dx.doi.org/10.1111/j.1440-1681.2012.05741.x] [PMID: 22725681]

Bertinato, J.; Swist, E.; Plouffe, L.J.; Brooks, S.P.J.; L’Abbé, M.R. Ctr2 is partially localized to the plasma membrane and stimulates copper uptake in COS-7 cells. Biochem. J., 2008, 409(3), 731-740.
[http://dx.doi.org/10.1042/BJ20071025] [PMID: 17944601]

Huang, C.P.; Fofana, M.; Chan, J.; Chang, C.J.; Howell, S.B. Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin. Metallomics, 2014, 6(3), 654-661.
[http://dx.doi.org/10.1039/c3mt00331k] [PMID: 24522273]

van den Berghe, P.V.E.; Folmer, D.E.; Malingré, H.E.M.; van Beurden, E.; Klomp, A.E.M.; van de Sluis, B.; Merkx, M.; Berger, R.; Klomp, L.W.J. Human copper transporter 2 is localized in late endosomes and lysosomes and facilitates cellular copper uptake. Biochem. J., 2007, 407(1), 49-59.
[http://dx.doi.org/10.1042/BJ20070705] [PMID: 17617060]

Blair, B.G.; Larson, C.A.; Adams, P.L.; Abada, P.B.; Pesce, C.E.; Safaei, R.; Howell, S.B. Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol. Pharmacol., 2011, 79(1), 157-166.
[http://dx.doi.org/10.1124/mol.110.068411] [PMID: 20930109]

Ala, A.; Walker, A.P.; Ashkan, K.; Dooley, J.S.; Schilsky, M.L. Wilson’s disease. Lancet, 2007, 369(9559), 397-408.
[http://dx.doi.org/10.1016/S0140-6736(07)60196-2] [PMID: 17276780]

Peña, K.; Coblenz, J.; Kiselyov, K. Brief exposure to copper activates lysosomal exocytosis. Cell Calcium, 2015, 57(4), 257-262.
[http://dx.doi.org/10.1016/j.ceca.2015.01.005] [PMID: 25620123]

Polishchuk, E.V.; Concilli, M.; Iacobacci, S.; Chesi, G.; Pastore, N.; Piccolo, P.; Paladino, S.; Baldantoni, D.; van IJzendoorn, S.C.D.; Chan, J.; Chang, C.J.; Amoresano, A.; Pane, F.; Pucci, P.; Tarallo, A.; Parenti, G.; Brunetti-Pierri, N.; Settembre, C.; Ballabio, A.; Polishchuk, R.S. Wilson disease protein ATP7B utilizes lysosomal exocytosis to maintain copper homeostasis. Dev. Cell, 2014, 29(6), 686-700.
[http://dx.doi.org/10.1016/j.devcel.2014.04.033] [PMID: 24909901]

Komatsu, M.; Sumizawa, T.; Mutoh, M.; Chen, Z.S.; Terada, K.; Furukawa, T.; Yang, X.L.; Gao, H.; Miura, N.; Sugiyama, T.; Akiyama, S. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res., 2000, 60(5), 1312-1316.
[PMID: 10728692]

Chauhan, S.S.; Liang, X.J.; Su, A.W.; Pai-Panandiker, A.; Shen, D.W.; Hanover, J.A.; Gottesman, M.M. Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines. Br. J. Cancer, 2003, 88(8), 1327-1334.
[http://dx.doi.org/10.1038/sj.bjc.6600861] [PMID: 12698203]

Kalayda, G.V.; Wagner, C.H.; Buß, I.; Reedijk, J.; Jaehde, U. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. BMC Cancer, 2008, 8(1), 175.
[http://dx.doi.org/10.1186/1471-2407-8-175] [PMID: 18565219]

Safaei, R.; Larson, B.J.; Cheng, T.C.; Gibson, M.A.; Otani, S.; Naerdemann, W.; Howell, S.B. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol. Cancer Ther., 2005, 4(10), 1595-1604.
[http://dx.doi.org/10.1158/1535-7163.MCT-05-0102] [PMID: 16227410]

Andrews, N.W. Regulated secretion of conventional lysosomes. Trends Cell Biol., 2000, 10(8), 316-321.
[http://dx.doi.org/10.1016/S0962-8924(00)01794-3] [PMID: 10884683]

Groth-Pedersen, L.; Jäättelä, M. Combating apoptosis and multidrug resistant cancers by targeting lysosomes. Cancer Lett., 2013, 332(2), 265-274.
[http://dx.doi.org/10.1016/j.canlet.2010.05.021] [PMID: 20598437]

Assmus, F.; Houston, J.B.; Galetin, A. Incorporation of lysosomal sequestration in the mechanistic model for prediction of tissue distribution of basic drugs. Eur. J. Pharm. Sci., 2017, 109, 419-430.
[http://dx.doi.org/10.1016/j.ejps.2017.08.014] [PMID: 28823852]

Medina, D.L.; Fraldi, A.; Bouche, V.; Annunziata, F.; Mansueto, G.; Spampanato, C.; Puri, C.; Pignata, A.; Martina, J.A.; Sardiello, M.; Palmieri, M.; Polishchuk, R.; Puertollano, R.; Ballabio, A. Transcriptional activation of lysosomal exocytosis promotes cellular clearance. Dev. Cell, 2011, 21(3), 421-430.
[http://dx.doi.org/10.1016/j.devcel.2011.07.016] [PMID: 21889421]

Yanes, R.E.; Tarn, D.; Hwang, A.A.; Ferris, D.P.; Sherman, S.P.; Thomas, C.R.; Lu, J.; Pyle, A.D.; Zink, J.I.; Tamanoi, F. Involvement of lysosomal exocytosis in the excretion of mesoporous silica nanoparticles and enhancement of the drug delivery effect by exocytosis inhibition. Small, 2013, 9, 697-704.
[http://dx.doi.org/10.1002/smll.201201811]

Boya, P.; Kroemer, G. Lysosomal membrane permeabilization in cell death. Oncogene, 2008, 27(50), 6434-6451.
[http://dx.doi.org/10.1038/onc.2008.310] [PMID: 18955971]

Dielschneider, R.F.; Eisenstat, H.; Mi, S.; Curtis, J.M.; Xiao, W.; Johnston, J.B.; Gibson, S.B. Lysosomotropic agents selectively target chronic lymphocytic leukemia cells due to altered sphingolipid metabolism. Leukemia, 2016, 30(6), 1290-1300.
[http://dx.doi.org/10.1038/leu.2016.4] [PMID: 26859075]

Lim, C.Y.; Zoncu, R. The lysosome as a command-and-control center for cellular metabolism. J. Cell Biol., 2016, 214(6), 653-664.
[http://dx.doi.org/10.1083/jcb.201607005] [PMID: 27621362]

Appelqvist, H.; Sandin, L.; Björnström, K.; Saftig, P.; Garner, B.; Öllinger, K.; Kågedal, K. Sensitivity to lysosome-dependent cell death is directly regulated by lysosomal cholesterol content. PLoS One, 2012, 7(11), e50262.
[http://dx.doi.org/10.1371/journal.pone.0050262] [PMID: 23166840]

Gyrd-Hansen, M.; Nylandsted, J.; Jäättelä, M. Heat shock protein 70 promotes cancer cell viability by safeguarding lysosomal integrity. Cell Cycle, 2004, 3(12), 1484-1485.
[http://dx.doi.org/10.4161/cc.3.12.1287] [PMID: 15539949]

Ostenfeld, M.S.; Fehrenbacher, N.; Høyer-Hansen, M.; Thomsen, C.; Farkas, T.; Jäättelä, M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res., 2005, 65(19), 8975-8983.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-0269] [PMID: 16204071]

Gotink, K.J.; Broxterman, H.J.; Honeywell, R.J.; Dekker, H.; de Haas, R.R.; Miles, K.M.; Adelaiye, R.; Griffioen, A.W.; Peters, G.J.; Pili, R.; Verheul, H.M.W. Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature. Oncoscience, 2014, 1(12), 844-853.
[http://dx.doi.org/10.18632/oncoscience.106] [PMID: 25621299]

Li, Y.; Sun, Y.; Jing, L.; Wang, J.; Yan, Y.; Feng, Y.; Zhang, Y.; Liu, Z.; Ma, L.; Diao, A. Lysosome inhibitors enhance the chemotherapeutic activity of doxorubicin in HepG2 cells. Chemotherapy, 2017, 62(2), 85-93.
[http://dx.doi.org/10.1159/000448802] [PMID: 27764836]

Wang, E.; Lee, M.D.; Dunn, K.W. Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug-resistant MES-SA/Dx5 uterine sarcoma cells. J. Cell. Physiol., 2000, 184(2), 263-274.
[http://dx.doi.org/10.1002/1097-4652(200008)184:2<263:AID-JCP15>3.0.CO;2-F] [PMID: 10867652]

Zhang, S.; Schneider, L.S.; Vick, B.; Grunert, M.; Jeremias, I.; Menche, D.; Müller, R.; Vollmar, A.M.; Liebl, J. Anti-leukemic effects of the V-ATPase inhibitor Archazolid. Oncotarget, 2015, 6(41), 43508-43528.
[http://dx.doi.org/10.18632/oncotarget.6180] [PMID: 26496038]

Dykstra, K.M.; Fay, H.R.S.; Massey, A.C.; Yang, N.; Johnson, M.; Portwood, S.; Guzman, M.L.; Wang, E.S. Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis. Blood Adv., 2021, 5(8), 2087-2100.
[http://dx.doi.org/10.1182/bloodadvances.2020002666] [PMID: 33877295]

Visser, N.; Lourens, H.J.; Huls, G.; Bremer, E.; Wiersma, V.R. Inhibition of autophagy does not re-sensitize acute myeloid leukemia cells resistant to cytarabine. Int. J. Mol. Sci., 2021, 22(5), 2337.
[http://dx.doi.org/10.3390/ijms22052337] [PMID: 33652766]

Bao, E.L.; Nandakumar, S.K.; Liao, X.; Bick, A.G.; Karjalainen, J.; Tabaka, M.; Gan, O.I.; Havulinna, A.S.; Kiiskinen, T.T.J.; Lareau, C.A.; de Lapuente Portilla, A.L.; Li, B.; Emdin, C.; Codd, V.; Nelson, C.P.; Walker, C.J.; Churchhouse, C.; de la Chapelle, A.; Klein, D.E.; Nilsson, B.; Wilson, P.W.F.; Cho, K.; Pyarajan, S.; Gaziano, J.M.; Samani, N.J.; Palotie, A.; Daly, M.; Jacob, H.; Matakidou, A.; Runz, H.; John, S.; Plenge, R.; McCarthy, M.; Hunkapiller, J.; Ehm, M.; Waterworth, D.; Fox, C.; Malarstig, A.; Klinger, K.; Call, K.; Mäkelä, T.; Kaprio, J.; Virolainen, P.; Pulkki, K.; Kilpi, T.; Perola, M.; Partanen, J.; Pitkäranta, A.; Kaarteenaho, R.; Vainio, S.; Savinainen, K.; Kosma, V-M.; Kujala, U.; Tuovila, O.; Hendolin, M.; Pakkanen, R.; Waring, J.; Riley-Gillis, B.; Matakidou, A.; Runz, H.; Liu, J.; Biswas, S.; Hunkapiller, J.; Waterworth, D.; Ehm, M.; Diogo, D.; Fox, C.; Malarstig, A.; Marshall, C.; Hu, X.; Call, K.; Klinger, K.; Gossel, M.; Ripatti, S.; Schleutker, J.; Perola, M.; Arvas, M.; Carpén, O.; Hinttala, R.; Kettunen, J.; Laaksonen, R.; Mannermaa, A.; Kujala, U.; Tuovila, O.; Hendolin, M.; Pakkanen, R.; Soininen, H.; Julkunen, V.; Remes, A.; Kälviäinen, R.; Hiltunen, M.; Peltola, J.; Tienari, P.; Rinne, J.; Ziemann, A.; Waring, J.; Esmaeeli, S.; Smaoui, N.; Lehtonen, A.; Eaton, S.; Runz, H.; Lahdenperä, S.; van Adelsberg, J.; Biswas, S.; Michon, J.; Kerchner, G.; Hunkapiller, J.; Bowers, N.; Teng, E.; Eicher, J.; Mehta, V.; Gormley, P.; Linden, K.; Whelan, C.; Xu, F.; Pulford, D.; Färkkilä, M.; Pikkarainen, S.; Jussila, A.; Blomster, T.; Kiviniemi, M.; Voutilainen, M.; Georgantas, B.; Heap, G.; Waring, J.; Smaoui, N.; Rahimov, F.; Lehtonen, A.; Usiskin, K.; Maranville, J.; Lu, T.; Bowers, N.; Oh, D.; Michon, J.; Mehta, V.; Kalpala, K.; Miller, M.; Hu, X.; McCarthy, L.; Eklund, K.; Palomäki, A.; Isomäki, P.; Pirilä, L.; Kaipiainen-Seppänen, O.; Huhtakangas, J.; Georgantas, B.; Waring, J.; Rahimov, F.; Lertratanakul, A.; Smaoui, N.; Lehtonen, A.; Close, D.; Hochfeld, M.; Bowers, N.; Michon, J.; Diogo, D.; Mehta, V.; Kalpala, K.; Bing, N.; Hu, X.; Gordillo, J.E.; Mars, N.; Laitinen, T.; Pelkonen, M.; Kauppi, P.; Kankaanranta, H.; Harju, T.; Smaoui, N.; Close, D.; Greenberg, S.; Chen, H.; Bowers, N.; Michon, J.; Mehta, V.; Betts, J.; Ghosh, S.; Salomaa, V.; Niiranen, T.; Juonala, M.; Metsärinne, K.; Kähönen, M.; Junttila, J.; Laakso, M.; Pihlajamäki, J.; Sinisalo, J.; Taskinen, M-R.; Tuomi, T.; Laukkanen, J.; Challis, B.; Peterson, A.; Hunkapiller, J.; Bowers, N.; Michon, J.; Diogo, D.; Chu, A.; Mehta, V.; Parkkinen, J.; Miller, M.; Muslin, A.; Waterworth, D.; Joensuu, H.; Meretoja, T.; Carpén, O.; Aaltonen, L.; Auranen, A.; Karihtala, P.; Kauppila, S.; Auvinen, P.; Elenius, K.; Popovic, R.; Waring, J.; Riley-Gillis, B.; Lehtonen, A.; Matakidou, A.; Schutzman, J.; Hunkapiller, J.; Bowers, N.; Michon, J.; Mehta, V.; Loboda, A.; Chhibber, A.; Lehtonen, H.; McDonough, S.; Crohns, M.; Kulkarni, D.; Kaarniranta, K.; Turunen, J.; Ollila, T.; Seitsonen, S.; Uusitalo, H.; Aaltonen, V.; Uusitalo-Järvinen, H.; Luodonpää, M.; Hautala, N.; Runz, H.; Strauss, E.; Bowers, N.; Chen, H.; Michon, J.; Podgornaia, A.; Mehta, V.; Diogo, D.; Hoffman, J.; Tasanen, K.; Huilaja, L.; Hannula-Jouppi, K.; Salmi, T.; Peltonen, S.; Koulu, L.; Harvima, I.; Kalpala, K.; Wu, Y.; Choy, D.; Michon, J.; Smaoui, N.; Rahimov, F.; Lehtonen, A.; Waterworth, D.; Davis, J.W.; Riley-Gillis, B.; Quarless, D.; Petrovski, S.; Liu, J.; Chen, C-Y.; Bronson, P.; Yang, R.; Maranville, J.; Biswas, S.; Chang, D.; Hunkapiller, J.; Bhangale, T.; Bowers, N.; Diogo, D.; Holzinger, E.; Gormley, P.; Wang, X.; Chen, X.; Hedman, Å.; Auro, K.; Wang, C.; Xu, E.; Auge, F.; Chatelain, C.; Kurki, M.; Ripatti, S.; Daly, M.; Karjalainen, J.; Havulinna, A.; Jalanko, A.; Palin, K.; Palta, P.; della Briotta Parolo, P.; Zhou, W.; Lemmelä, S.; Rivas, M.; Harju, J.; Palotie, A.; Lehisto, A.; Ganna, A.; Llorens, V.; Karlsson, A.; Kristiansson, K.; Arvas, M.; Hyvärinen, K.; Ritari, J.; Wahlfors, T.; Koskinen, M.; Carpén, O.; Kettunen, J.; Pylkäs, K.; Kalaoja, M.; Karjalainen, M.; Mantere, T.; Kangasniemi, E.; Heikkinen, S.; Mannermaa, A.; Laakkonen, E.; Kononen, J.; Kallio, L.; Soini, S.; Partanen, J.; Pitkänen, K.; Vainio, S.; Savinainen, K.; Kosma, V-M.; Kuopio, T.; Jalanko, A.; Kajanne, R.; Lyhs, U.; Kurki, M.; Karjalainen, J.; della Briotta Parola, P.; Rüeger, S.; Lehistö, A.; Zhou, W.; Kanai, M.; Laivuori, H.; Havulinna, A.; Lemmelä, S.; Kiiskinen, T.; Kaunisto, M.; Harju, J.; Kilpeläinen, E.; Sipilä, T.P.; Brein, G.; Dada, O.A.; Awaisa, G.; Shcherban, A.; Sipilä, T.; Donner, K.; Loukola, A.; Laiho, P.; Sistonen, T.; Kaiharju, E.; Laukkanen, M.; Järvensivu, E.; Lähteenmäki, S.; Männikkö, L.; Wong, R.; Mattsson, H.; Kristiansson, K.; Lemmelä, S.; Hiekkalinna, T.; Jiménez, M.G.; Palta, P.; Pärn, K.; Nunez-Fontarnau, J.; Laitinen, T.; Siirtola, H.; Tabuenca, J.G.; Agee, M.; Alipanahi, B.; Auton, A.; Bell, R.K.; Bryc, K.; Elson, S.L.; Fontanillas, P.; Furlotte, N.A.; Hinds, D.A.; Huber, K.E.; Kleinman, A.; Litterman, N.K.; McCreight, J.C.; McIntyre, M.H.; Mountain, J.L.; Noblin, E.S.; Northover, C.A.M.; Pitts, S.J.; Sathirapongsasuti, J.F.; Sazonova, O.V.; Shelton, J.F.; Shringarpure, S.; Tian, C.; Tung, J.Y.; Vacic, V.; Wilson, C.H.; Regev, A.; Palotie, A.; Neale, B.M.; Dick, J.E.; Natarajan, P.; O’Donnell, C.J.; Daly, M.J.; Milyavsky, M.; Kathiresan, S.; Sankaran, V.G. Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells. Nature, 2020, 586(7831), 769-775.
[http://dx.doi.org/10.1038/s41586-020-2786-7] [PMID: 33057200]

Seebacher, N.A.; Lane, D.J.R.; Jansson, P.J.; Richardson, D.R. Glucose modulation induces lysosome formation and increases lysosomotropic drug sequestration via the P-Glycoprotein drug transporter. J. Biol. Chem., 2016, 291(8), 3796-3820.
[http://dx.doi.org/10.1074/jbc.M115.682450] [PMID: 26601947]

Seebacher, N.A.; Richardson, D.R.; Jansson, P.J. A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC. Cell Death Dis., 2016, 7(12), e2510.
[http://dx.doi.org/10.1038/cddis.2016.381] [PMID: 27906178]

Jansson, P.J.; Yamagishi, T.; Arvind, A.; Seebacher, N.; Gutierrez, E.; Stacy, A.; Maleki, S.; Sharp, D.; Sahni, S.; Richardson, D.R. Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp). J. Biol. Chem., 2015, 290(15), 9588-9603.
[http://dx.doi.org/10.1074/jbc.M114.631283] [PMID: 25720491]

Lovejoy, D.B.; Jansson, P.J.; Brunk, U.T.; Wong, J.; Ponka, P.; Richardson, D.R. Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res., 2011, 71(17), 5871-5880.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-1218] [PMID: 21750178]

Yuan, J.; Lovejoy, D.B.; Richardson, D.R. Novel di-2-pyridyl–derived iron chelators with marked and selective antitumor activity: In vitro and in vivo assessment. Blood, 2004, 104(5), 1450-1458.
[http://dx.doi.org/10.1182/blood-2004-03-0868] [PMID: 15150082]

Gutierrez, E.M.; Seebacher, N.A.; Arzuman, L.; Kovacevic, Z.; Lane, D.J.R.; Richardson, V.; Merlot, A.M.; Lok, H.; Kalinowski, D.S.; Sahni, S.; Jansson, P.J.; Richardson, D.R. Lysosomal membrane stability plays a major role in the cytotoxic activity of the anti-proliferative agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT). Biochim. Biophys. Acta Mol. Cell Res., 2016, 1863(7), 1665-1681.
[http://dx.doi.org/10.1016/j.bbamcr.2016.04.017] [PMID: 27102538]

Świtalska, M.; Filip-Psurska, B.; Milczarek, M.; Psurski, M.; Moszyńska, A.; Dąbrowska, A.M.; Gawrońska, M.; Krzymiński, K.; Bagiński, M.; Bartoszewski, R.; Wietrzyk, J. Combined anticancer therapy with imidazoacridinone analogue C‐1305 and paclitaxel in human lung and colon cancer xenografts—Modulation of tumour angiogenesis. J. Cell. Mol. Med., 2022, 26(14), 3950-3964.
[http://dx.doi.org/10.1111/jcmm.17430 ] [PMID: 35701366]

Chen, N.; Kommidi, H.; Guo, H.; Wu, A.P.; Zhang, Z.; Yang, X.; Xia, L.; An, F.; Ting, R. A lysosome specific, acidic-pH activated, near-infrared Bodipy fluorescent probe for noninvasive, long-term, in vivo tumor imaging. Mater. Sci. Eng. C, 2020, 111, 110762.
[http://dx.doi.org/10.1016/j.msec.2020.110762] [PMID: 32279764]

Gui, L.; Wang, K.; Wang, Y.; Yan, J.; Liu, X.; Guo, J.; Liu, J.; Deng, D.; Chen, H.; Yuan, Z. Monitoring the pH fluctuation of lysosome under cell stress using a near-infrared ratiometric fluorescent probe. Chin. Chem. Lett., 2023, 34(3), 107586.
[http://dx.doi.org/10.1016/j.cclet.2022.06.009]

Sun, Y.; Zhou, X.; Sun, L.; Zhao, X.; He, Y.; Gao, G.; Han, W.; Zhou, J. Lysosome-targeting red fluorescent probe for broad carboxylesterases detection in breast cancer cells. Chin. Chem. Lett., 2022, 33(9), 4229-4232.
[http://dx.doi.org/10.1016/j.cclet.2022.01.087]

Zong, D.; Hååg, P.; Yakymovych, I.; Lewensohn, R.; Viktorsson, K. Chemosensitization by phenothiazines in human lung cancer cells: impaired resolution of γH2AX and increased oxidative stress elicit apoptosis associated with lysosomal expansion and intense vacuolation. Cell Death Dis., 2011, 2(7), e181.
[http://dx.doi.org/10.1038/cddis.2011.62] [PMID: 21776019]

Zong, D.; Zielinska-Chomej, K.; Juntti, T.; Mörk, B.; Lewensohn, R.; Hååg, P.; Viktorsson, K. Harnessing the lysosome-dependent antitumor activity of phenothiazines in human small cell lung cancer. Cell Death Dis., 2014, 5(3), e1111.
[http://dx.doi.org/10.1038/cddis.2014.56] [PMID: 24625970]

Fehrenbacher, N.; Bastholm, L.; Kirkegaard-Sørensen, T.; Rafn, B.; Bøttzauw, T.; Nielsen, C.; Weber, E.; Shirasawa, S.; Kallunki, T.; Jäättelä, M. Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2. Cancer Res., 2008, 68(16), 6623-6633.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-0463] [PMID: 18701486]

Petersen, N.H.T.; Olsen, O.D.; Groth-Pedersen, L.; Ellegaard, A.M.; Bilgin, M.; Redmer, S.; Ostenfeld, M.S.; Ulanet, D.; Dovmark, T.H.; Lønborg, A.; Vindeløv, S.D.; Hanahan, D.; Arenz, C.; Ejsing, C.S.; Kirkegaard, T.; Rohde, M.; Nylandsted, J.; Jäättelä, M. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell, 2013, 24(3), 379-393.
[http://dx.doi.org/10.1016/j.ccr.2013.08.003] [PMID: 24029234]

Sukhai, M.A.; Prabha, S.; Hurren, R.; Rutledge, A.C.; Lee, A.Y.; Sriskanthadevan, S.; Sun, H.; Wang, X.; Skrtic, M.; Seneviratne, A.; Cusimano, M.; Jhas, B.; Gronda, M.; MacLean, N.; Cho, E.E.; Spagnuolo, P.A.; Sharmeen, S.; Gebbia, M.; Urbanus, M.; Eppert, K.; Dissanayake, D.; Jonet, A.; Dassonville-Klimpt, A.; Li, X.; Datti, A.; Ohashi, P.S.; Wrana, J.; Rogers, I.; Sonnet, P.; Ellis, W.Y.; Corey, S.J.; Eaves, C.; Minden, M.D.; Wang, J.C.Y.; Dick, J.E.; Nislow, C.; Giaever, G.; Schimmer, A.D. Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors. J. Clin. Invest., 2013, 123(1), 315-328.
[http://dx.doi.org/10.1172/JCI64180] [PMID: 23202731]

Fernandes, I.; Vale, N.; de Freitas, V.; Moreira, R.; Mateus, N.; Gomes, P. Anti-tumoral activity of imidazoquines, a new class of antimalarials derived from primaquine. Bioorg. Med. Chem. Lett., 2009, 19(24), 6914-6917.
[http://dx.doi.org/10.1016/j.bmcl.2009.10.081] [PMID: 19896373]

Zhang, Y.; Li, Y.; Li, Y.; Li, R.; Ma, Y.; Wang, H.; Wang, Y. Chloroquine inhibits MGC803 gastric cancer cell migration via the Toll-like receptor 9/nuclear factor kappa B signaling pathway. Mol. Med. Rep., 2015, 11(2), 1366-1371.
[http://dx.doi.org/10.3892/mmr.2014.2839] [PMID: 25369757]

Erdal, H.; Berndtsson, M.; Castro, J.; Brunk, U.; Shoshan, M.C.; Linder, S. Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proc. Natl. Acad. Sci., 2005, 102(1), 192-197.
[http://dx.doi.org/10.1073/pnas.0408592102] [PMID: 15618392]